Hyperplasia

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

Retrieved on: 
Friday, May 3, 2024
Weill Cornell Medical Center, Hyperplasia, Weill Cornell Medicine, Patient, Neurocrine Biosciences, Clinical Pediatrics, CAH, Safety, GC, Androstenedione, Food, Male, Congenital adrenal hyperplasia, Observation, Obesity, Disease, D.O, Hirsutism, Diagnosis, Poster, Associate, Adrenocorticotropic hormone, Natural history, SAN, Pharmaceutical industry

SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.

Key Points: 
  • SAN DIEGO, May 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
  • These new data were presented at the Pediatric Endocrine Society 2024 Annual Meeting in Chicago.
  • Baseline characteristics of the subjects who enrolled in the CAHtalyst Pediatric Phase 3 study were presented (Poster# 56).
  • Neurocrine Biosciences also presented glucocorticoid treatment patterns from a recent cohort of pediatric and adult patients participating in the CAHtalog Registry (Poster# 51).

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

Retrieved on: 
Monday, April 1, 2024
Death, Adenoma, Doctor of Pharmacy, Risk, Patient, Oncology, Syndrome, Hyperglycemia, Hyperplasia, Hypertension, Pharmaceutical industry

“Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.

Key Points: 
  • “Hypercortisolism with adrenal etiology affects many patients and is associated with serious cardiometabolic comorbidities, including hypertension and hyperglycemia, and increased risk of premature death,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.
  • “GRADIENT is the first prospective placebo-controlled study to be conducted exclusively in these patients with Cushing’s syndrome.
  • We expect data from GRADIENT in the fourth quarter of this year.”
    GRADIENT is a randomized, double-blind, placebo-controlled trial conducted at sites in the United States, Europe and Israel.
  • One-hundred thirty-seven patients were randomized 1:1 to receive relacorilant or placebo for 22 weeks.

Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer

Retrieved on: 
Monday, March 4, 2024
Urology, ISC, Overalls, Polyp, Adenoma, Extrapyramidal system, Classification, Cancer, Health, Patient, Diagnosis, Research, Gastroenterology, Hyperplasia, Workflow, Medical device

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.

Key Points: 
  • NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™.
  • The platform will offer computer aided devices for detection, classification and characterization of lesions and tissue irregularities in the colon (colon cancer) and the upper gastrointestinal tract (esophageal and gastric cancer).
  • Validation is commencing with its AI software tool, namely, Helga iCAP™ for the detection of colonic conditions.
  • As such, Intelligent Scopes collaborates with key stakeholders including clinicians, academia, and equipment manufacturers to provide tools that can aid endoscopists in providing optimal care to patients.

InventHelp Inventor Develops Means to Create a Urine Passage for Enlarged Prostate Tissue (LBT-8305)

Retrieved on: 
Monday, February 12, 2024
DEPT, Urination, Incidence, Multimedia, Suite, Quality of life, Pain, Prostate, Hyperplasia, Sale, FLO, BPH, Urine

My design would eliminate the need for a man with an enlarged prostate to continually wake throughout the night to urinate."

Key Points: 
  • My design would eliminate the need for a man with an enlarged prostate to continually wake throughout the night to urinate."
  • The invention provides an effective way to treat prostate gland enlargement or benign prostatic hyperplasia.
  • In doing so, it reduces the incidence of urine leakage, frequent urination during the night, and urgency or inability to urinate.
  • 22-LBT-8305, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

Retrieved on: 
Tuesday, May 9, 2023
Blood pressure, Primary aldosteronism, CT, CXCR4, Heart failure, Gland, Hypertension, Stroke, APA, TecDAX, BAH, Nuclear medicine, File association, Trial of the century, Investigator, Aldosterone, Patient, Risk, Hyperplasia, Adenoma, Chief medical informatics officer, Surgeon, Hudson Institute, ISIN, Principal, Monash, AVS, Eckert, Pharmaceutical industry, Medical imaging, Gallium

Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.

Key Points: 
  • Primary Aldosteronism (PA) refers to the hypersecretion of aldosterone, a hormone that increases blood pressure and consequently leads to high vascular morbidity including stroke and heart failure.
  • It would most likely have a large impact on clinical practice and enable a large number of hypertension patients to be cured.
  • The study in Australia is in line with clinical activities in Europe and in the USA, which are supported by PentixaPharm.
  • [68Ga]Ga-PentixaFor is being developed by Eckert & Ziegler's subsidiary PentixaPharm GmbH also as a superiorly sensitive diagnostic for a portfolio of hematooncological malignancies.

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
Observation, SAN, Colon, Retina, Tissue, Diabetic retinopathy, GGT, Research, Security (finance), Therapy, Collaboration, Inflammatory bowel disease, Eye, Regeneration, Insurance, Cochlea, Hepatitis, Patient, Expense, Ulcerative colitis, Development, Coronavirus, COVID-19, Growth, AST, Soft tissue injury, SAD, Lung, Partnership, Degenerative disease, Annual report, Homeostasis, Liver, Safety, Probability, Kidney, Administration, Hyperplasia, Hearing loss, Central nervous system, Boehringer Ingelheim, Alcoholic hepatitis, Disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, WNT

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter of 2022 and provided a corporate update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter of 2022 and provided a corporate update.
  • Surrozen will be re-evaluating the overall clinical development timeline for this program and will provide an update at the appropriate time.
  • Financial Results for the Third Quarter Ended September 30, 2022
    Cash Position: Cash, cash equivalents and marketable securities for the third quarter ended September 30, 2022 were $78.4 million, compared to $92.7 million as of June 30, 2022.
  • However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.

Continued Clinical Success Reported with Unique Cutting-Edge Vessel Prep Device

Retrieved on: 
Thursday, June 30, 2022
CE marking, Fistula, FDA, Tri-City Medical Center, View, Patient, PTA, Multimedia, Hyperplasia, Angioplasty, CE, Dissection, Technology, Dural arteriovenous fistula, CS, PARK, XO, ATM, Dilation, Stenosis, Aluminium, Natural rubber, Medical device

PARK CITY, Utah, June 30, 2022 /PRNewswire/ -- Transit Scientific shares successful outcomes on multiple fistula and graft cases using its XO Score Sheath Platform along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons.

Key Points: 
  • First-of-its-kindmetal-alloy scoring, cutting, and constraining structure (CS) device continues to elevate angioplasty treatment of chronic dialysis fistulas and grafts.
  • The lesion was resistant to initial treatment using a high-pressure PTA inflated to 40 atmospheres (ATM).
  • The lesion was then treated with the XO Scoredevice and followed by effacement of the stenosis with standard balloon PTA inflated to nominal pressure (9ATM).
  • When the angioplasty balloon is inflated, the struts/grooves expand with the balloon and rotate 90 to apply focal force to the vessel.

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Retrieved on: 
Tuesday, May 24, 2022
Epithelium, CEO, Inflammation, Degenerative disease, UC, Edu, Hyperplasia, Toxicology, Retina, Soft tissue injury, Disease, DDW, Ulcerative colitis, U.S. Securities and Exchange Commission, Homeostasis, Infection, Immunoglobulin G, Kinetics, Hearing loss, Coronavirus, GLP, Liver, FZD5, Cochlea, COVID-19, Trial of the century, SCID, Kidney, Research, IBD, Mouse, Inflammatory bowel disease, SAN, RATS, Alcoholic hepatitis, DSS, Probability, Fibrosis, Lists of disasters, Forward-looking statement, Tissue, Central nervous system, Major, Liver injury, Regeneration, Hepatocyte, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, Institute of Liver and Biliary Sciences, GLOBE, Pharmaceutical industry, Medical imaging, Dietary supplement, WNT

These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.

Key Points: 
  • These data represent the important progress and significant advances made in the scientific understanding of our lead therapeutic candidates, SZN-1326 and SZN-043, said Craig Parker, CEO of Surrozen.
  • The data further show that SZN-1326 also reduced stromal and immune cytokine signaling and immune cell infiltration.
  • Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.
  • However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.

Teleflex Announces Regulatory Clearance for its UroLift® System in China for the Treatment of Benign Prostatic Hyperplasia (BPH)

Retrieved on: 
Thursday, May 19, 2022
American Urological Association, Teleflex, Hyperplasia, U.S. Securities and Exchange Commission, Hematuria, European Association of Urology, National Medical Products Administration, Pelvic pain, Infection, Prostate, TFX, Patient, Solution, BPH, Health, Emergency medicine, Association, Anesthesia, Urology, Prostatic urethral lift, Heat, Bleeding, Man, NMPA, Standard of care, Security (finance), Radiology, NYSE, Annual report, GLOBE, Pharmaceutical industry, Medical imaging, Dysuria

Treatment with the UroLift System is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition which may cause bothersome urinary symptoms in men.

Key Points: 
  • Treatment with the UroLift System is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition which may cause bothersome urinary symptoms in men.
  • As a key component of our durable growth strategy, Teleflex remains committed to making the UroLift System the standard of care in the treatment of BPH globally.
  • Ben Cheong, Managing Director in China for Teleflex said, Launching the UroLift System in China and offering new treatment options for patients with BPH is exciting.
  • The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Retrieved on: 
Monday, May 16, 2022
Bowel obstruction, Senior, Anti-inflammatory, Colon, Wall, Inflammation, Epithelium, Degenerative disease, UC, Disease, Hyperplasia, Soft tissue injury, U.S. Securities and Exchange Commission, Retina, Ulcerative colitis, Patient, Biology, Homeostasis, Infection, Hearing loss, Coronavirus, Wnt signaling pathway, Liver, Cochlea, COVID-19, Colitis, Cell, LRP6, Kidney, Research, Inflammatory bowel disease, SAN, Hepatology, DSS, Probability, Lists of disasters, Forward-looking statement, Central nervous system, Technology, Regeneration, Lists of diseases, Lung, Therapy, Security (finance), Eye, Annual report, Hepatitis, ECCO, Tissue, GLOBE, Pharmaceutical industry, FZD5, WNT

The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.

Key Points: 
  • The results seen with one of Surrozens proprietary Wnt mimetic antibodies highlight the potential for this novel approach to treating inflammatory bowel disease.
  • SZN-1326 demonstrated the most rapid and robust repair of the injured colon epithelium without affecting normal epithelium and without causing hyperplasia.
  • In the intestine, Wnt signaling plays an important role in maintaining integrity of the epithelium as part of tissue homeostasis and during injury repair.
  • Surrozen designed an antibody-based platform that generates potent Wnt mimetics, which specifically target select Fzd receptors and co-receptors.